In current clinical practice [55], crizotinib has been a standard care for patients with ALK-rearranged NSCLC, and ALK rearrangement should be routinely analyzed in patients with advanced NSCLC, particularly for patients with wild-type EGFR NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.